Markets:

Overview

News

Currencies

International

Treasuries

Contineum Therapeutics, Inc. - Common stock (NQ:CTNM)

12.60 +0.69 (+5.79%)

Streaming Delayed Price Updated: 10:35 AM EDT, Jun 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Contineum Therapeutics, Inc. - Common stock

< Previous 1 2 Next >

Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference

June 01, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 15, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference

May 12, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference

May 11, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones

May 05, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 01, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain

April 30, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 13, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

March 05, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference

March 03, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 18, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 28, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering

December 11, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Announces Proposed $75.0 Million Public Offering

December 11, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference

November 24, 2025

From Contineum Therapeutics

Via Business Wire

Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

November 20, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

October 30, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

September 18, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Present at September Investor Conferences

August 28, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones

August 05, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

June 25, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 15, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

May 14, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

April 28, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

March 17, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum

March 12, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

March 06, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791

March 04, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference

March 03, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

January 08, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.